The DOI matches its Crossref record.
The Activation State of p38 Mitogen-Activated Protein Kinase Determines the Efficiency of ATP Competition for Pyridinylimidazole Inhibitor Binding
Abstract
The serine/threonine kinase p38 is a ubiquitous, highly conserved, stress responsive, signal-transducing enzyme. It regulates the production of proinflammatory mediators and is the target of the cytokine synthesis inhibitory pyridinylimidazoles. We have expressed human p38 in Drosophila S2 cells and characterized preparations of mixed unphosphorylated/monophosphorylated (inactive) and homogeneously diphosphorylated (active) forms of the enzyme. We observed that only the active preparation of the enzyme has significant kinase activity when assayed using an ATF2-GST fusion protein as the substrate. We determined that the value of KM[ATP] in this reaction is 25 microM and that the pyridinylimidazole inhibitor of p38 kinase activity, SB203580, competes with ATP. We have found that a tritiated pyridinylimidazole, SB202190, has an equal affinity for both the active and inactive forms of the enzyme and that SB203580 competes with it equally well for binding to either form of the enzyme. However, ATP can compete with the tritiated inhibitor for binding to only the active form of the enzyme. Further, we demonstrate in vivo that at concentrations consistent with its IC50 as a cytokine inhibitor, SB203580 can inhibit stimulus-induced phosphorylation of p38 at the Thr-Gly-Tyr activation motif. Our observations suggest that pyridinylimidazoles may block the biological activity of p38 kinase by binding to the inactive form of p38 and reducing its rate of activation. Under these conditions, ATP would not effectively compete with the inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
MAPK cascade signalling and synaptic plasticity
Thomas, G. M., & Huganir, R. L. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1346 · Cited by 1,454
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430
Kaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
p38 MAPK signalling cascades in inflammatory disease
Herlaar, E., & Brown, Z. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01544-0 · Cited by 564
MAPKK-Independent Activation of p38α Mediated by TAB1-Dependent Autophosphorylation of p38α
Ge, B., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R. J., Luo, Y., & Han, J. (2002) · Science · doi:10.1126/science.1067289 · Cited by 534
Inhibition of p38 MAP kinase as a therapeutic strategy
Lee, J. C., Kumar, S., Griswold, D. E., Underwood, D. C., Votta, B. J., & Adams, J. L. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00206-x · Cited by 455
Pharmacological inhibitors of MAPK pathways
English, J. M., & Cobb, M. H. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01865-4 · Cited by 447
New Insights into the Control of MAP Kinase Pathways
English, J., Pearson, G., Wilsbacher, J., Swantek, J., Karandikar, M., Xu, S., & Cobb, M. H. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4687 · Cited by 434
The many paths to p38 mitogen-activated protein kinase activation in the immune system
Ashwell, J. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1865 · Cited by 370
p38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic Potentials
Lee, J. C., Kassis, S., Kumar, S., Badger, A., & Adams, J. L. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00008-x · Cited by 348
Kumar, S., Jiang, M. S., Adams, J. L., & Lee, J. C. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1454 · Cited by 299
Storniolo, C. E., Roselló-Catafau, J., Pintó, X., Mitjavila, M. T., & Moreno, J. J. (2014) · Redox Biology · doi:10.1016/j.redox.2014.07.001 · Cited by 121
Live-cell imaging of human liver fibrosis using hepatic micro-organoids
Guan, Y., Fang, Z., Hu, A., Roberts, S., Wang, M., Ren, W., Johansson, P. K., Heilshorn, S. C., Enejder, A., & Peltz, G. (2025) · JCI Insight · doi:10.1172/jci.insight.187099 · Cited by 6
Metadata
- Authors
- Frantz, B., Klatt, T., Pang, M., Parsons, J., Rolando, A., Williams, H., Tocci, M. J., O'Keef, S. J., & O'Neill, E. A.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1998-09-01
- Volume
- 37
- Issue
- 39
- Pages
- 13846-13853
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2082594472
- Cited by
- 200
- References
- 0
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.